<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An announcement from Apellis Pharmaceuticals ( (APLS) ) is now available. On April 28, 2026, Apellis Pharmaceuticals’ compensation committee approved an amendment and restatement of its Executive Separation Benefits and Retention Plan in connection with the pending merger with Biogen. The updated plan, effective upon the closing of the merger, accelerates full vesting of unvested rights to payments on converted options and RSU awards for participating executives if they are terminated without cause or resign for good reason before full vesting. The amendment also revises the definition of “good reason” so that C-level officers, including all named executive officers, can treat certain changes in role or scope resulting from Apellis becoming a subsidiary as qualifying events. These changes enhance executive protections and retention incentives around the Biogen transaction, potentially affecting leadership stability and the distribution of merger-related equity value to senior management. The most recent analyst rating on (APLS) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page. Spark’s Take on APLS Stock According to Spark, TipRanks’ AI Analyst, APLS is a Neutral. The score is held back primarily by weak technical momentum and an uneven underlying financial profile despite a 2025 profitability/cash-flow inflection. Offsetting these negatives, the earnings call points to improving commercial traction (especially EMPAVELI) and solid liquidity, but guidance also flags continued net-revenue pressure from gross-to-net/free-goods dynamics and higher investment spend. To see Spark’s full report on APLS stock, click here. More about Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, with its executives participating in equity-based compensation programs tied to the company’s corporate and transactional activities. The company operates under a Delaware corporate structure and maintains an Executive Separation Benefits and Retention Plan to govern leadership compensation in change-of-control scenarios. Average Trading Volume: 4,928,135 Technical Sentiment Signal: Buy Current Market Cap: $5.24B For an in-depth examination of APLS stock, go to TipRanks’ Overview page.</div>

BIIB

APLS

LABU

Apellis Pharmaceuticals has updated its Executive Separation Benefits and Retention Plan in light of its merger with Biogen. The amendment, effective upon merger closure, accelerates vesting of unvested payments for executives terminated without cause or resigning for good reason. It also revises the definition of “good reason” for C-level officers. This aims to enhance executive protections and retention incentives. Analysts rate APLS stock as a Hold with a $41.00 price target, citing weak technical momentum but improving commercial traction and solid liquidity.

Apellis Updates Executive Separation Plan Amid Biogen Merger